Supernus Pharmaceuticals EPS - Earnings per Share 2011-2023 | SUPN
Supernus Pharmaceuticals eps - earnings per share from 2011 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Supernus Pharmaceuticals Annual EPS |
| 2023 |
$0.02 |
| 2022 |
$1.04 |
| 2021 |
$0.98 |
| 2020 |
$2.36 |
| 2019 |
$2.10 |
| 2018 |
$2.05 |
| 2017 |
$1.08 |
| 2016 |
$1.76 |
| 2015 |
$0.28 |
| 2014 |
$-0.26 |
| 2013 |
$-2.90 |
| 2012 |
$-2.72 |
| 2011 |
$31.39 |
| 2010 |
$-26.38 |
| Supernus Pharmaceuticals Quarterly EPS |
| 2023-12-31 |
$0.04 |
| 2023-09-30 |
$-0.29 |
| 2023-06-30 |
$-0.02 |
| 2023-03-31 |
$0.29 |
| 2022-12-31 |
$0.44 |
| 2022-09-30 |
$0.03 |
| 2022-06-30 |
$0.14 |
| 2022-03-31 |
$0.43 |
| 2021-12-31 |
$0.04 |
| 2021-09-30 |
$0.40 |
| 2021-06-30 |
$0.43 |
| 2021-03-31 |
$0.11 |
| 2020-12-31 |
$0.57 |
| 2020-09-30 |
$0.74 |
| 2020-06-30 |
$0.65 |
| 2020-03-31 |
$0.40 |
| 2019-12-31 |
$0.61 |
| 2019-09-30 |
$0.54 |
| 2019-06-30 |
$0.61 |
| 2019-03-31 |
$0.34 |
| 2018-12-31 |
$0.47 |
| 2018-09-30 |
$0.52 |
| 2018-06-30 |
$0.57 |
| 2018-03-31 |
$0.49 |
| 2017-12-31 |
$0.28 |
| 2017-09-30 |
$0.29 |
| 2017-06-30 |
$0.32 |
| 2017-03-31 |
$0.19 |
| 2016-12-31 |
$0.32 |
| 2016-09-30 |
$1.18 |
| 2016-06-30 |
$0.18 |
| 2016-03-31 |
$0.08 |
| 2015-12-31 |
$0.14 |
| 2015-09-30 |
$0.08 |
| 2015-06-30 |
$0.04 |
| 2015-03-31 |
$0.02 |
| 2014-12-31 |
$0.10 |
| 2014-09-30 |
$-0.06 |
| 2014-06-30 |
$0.08 |
| 2014-03-31 |
$-0.38 |
| 2013-12-31 |
$-0.63 |
| 2013-09-30 |
$-0.78 |
| 2013-06-30 |
$-0.89 |
| 2013-03-31 |
$-0.60 |
| 2012-12-31 |
$4.49 |
| 2012-09-30 |
$-0.55 |
| 2012-06-30 |
$-0.61 |
| 2012-03-31 |
$-6.05 |
| 2011-12-31 |
$40.14 |
| 2011-09-30 |
$-6.64 |
| 2011-06-30 |
$-5.17 |
| 2011-03-31 |
$-7.48 |
| 2010-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.721B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
